The Australasian Leukaemia and Lymphoma Group are the Sponsors of a new trial for Epstein Barr Virus (EBV) positive lymphoma patients, which will be recruiting at Sir Charles Gairdner Hospital:

Trebl-1 (NHL31)


Lymphomas that are associated with viruses can be difficult to treat. Until now there are no treatments available that specifically target EBV.

The new treatment is a combination of ibrutinib, rituximab, valaciclovir, and 3rd Party EBV-specific T cells (a type of white blood cell).

It is hoped this research will demonstrate that the infusions, in combination with ibrutinib, will be a safe and effective therapy for EBV positive lymphoma patients.

Visit: for further information